Objective-To determine whether tissue angiotensin converting enzyme (ACE) is increased in synovia from patients with rheumatoid arthritis, osteoarthritis or chondromalacia patellae. Methods-Sections of synovia from patients with rheumatoid arthritis (n = 7), osteoarthritis (n = 7) or chondromalacia patellae (n = 6) were tested for immunoreactivity for ACE, and for binding of the ACE inhibitor [ 
Angiotensin converting enzyme (ACE, EC 3.4.15.1) is a membrane metallopeptidase that participates in tissue regulatory peptide systems involving angiotensin II (ANG II), bradykinin and substance P. 1 ACE catalyses the formation of ANG II from its inactive precursor, ANG I, which itself is generated by cleavage of angiotensinogen by the protease renin. ANG II exerts its biological eVects via specific, cell surface receptors, of which two major subtypes, named AT 1 and AT 2 receptors, have been identified in humans. 2 ANG II is a potent vasoconstrictor, and can stimulate angiogenesis, fibroblast proliferation, collagen synthesis and growth factor expression, each mediated by AT 1 receptors.
3-7 ACE expression is upregulated by fibroblasts and myofibroblasts after tissue injury. 8 9 Furthermore, ACE inhibitors and AT 1 receptor antagonists can inhibit interstitial hypertrophy, hyperplasia and angiogenesis in a variety of tissues. 3 10-13 Hypertrophy, hyperplasia and angiogenesis also are characteristic of persistent rheumatoid synovitis. ACE activity is raised in synovial fluids from patients with rheumatoid arthritis compared with those with osteoarthritis, and rheumatoid synovial explants release ACE activity into their culture medium indicating local synthesis. 14 15 ACE, however, is primarily a membrane bound peptidase, and tissue ACE may be more important than soluble ACE in the local generation of ANG II. 16 In human synovium, ACE-like immunoreactivity (ACE-LI) is localised both to vascular endothelium, and to fibroblast-like and some macrophagelike cells in the synovial stroma. 17 It is currently unknown, however, whether tissue ACE is increased in either or both of these synovial compartments in rheumatoid arthritis. Increased tissue ACE could potentiate synovial hypertrophy and hyperplasia in rheumatoid arthritis through the increased generation of ANG II.
[ 18 19 Immunohistochemistry is a sensitive technique for localising ACE immunoreactivity and quantifying the proportion of tissue components expressing ACE. Quantitative in vitro receptor autoradiography permits the density of ACE-like binding sites to be measured and pharmacologically characterised. A combination of the two techniques performed on the same tissue samples provides a powerful tool to localise and quantify ACE at the microscopic level in human synovium.
We have now used quantitative in vitro autoradiography with [ 125 I]351A and immunohistochemistry to test whether tissue ACE levels are increased in vascular and stromal synovial compartments in human arthritis.
Methods

PATIENTS
Human synovium was collected at joint arthroplasty from patients with osteoarthritis or rheumatoid arthritis, diagnosed according to American Rheumatism Association criteria, 20 21 and from patients undergoing carbon fibre resurfacing of articular cartilage for chondromalacia patellae. Patients with chondromalacia patellae had radiographically normal knees, with cartilage defects observed at arthroscopy.
Equilibrium 
IMMUNOHISTOCHEMISTRY
Consecutive sections to those used in binding studies were used for immunolocalisation of ACE using the aYnity purified rabbit polyclonal antihuman ACE antibody RH179. 24 Cryostat sections (10 µm thick) were stained by the avidin-biotin complex (ABC) method. 25 26 In brief, sections were fixed in cold acetone for five minutes at 4°C, incubated with primary antibody overnight at 4°C, then with biotinylated goat antirabbit IgG for 30 minutes, avidin-biotin-peroxidase complex for 30 minutes and finally developed in diaminobenzidine with glucose oxidase enhancement, dehydrated and mounted in dibutylpthalate polystyrene xylene (Raymond Lamb, London, UK)
QUANTIFICATION OF IMMUNOHISTOCHEMISTRY AND CELLULARITY
The fraction occupied by ACE immunoreactivity of synovial tissue section area within 200 µm of the synovial surface was measured using a KS300 image analysis system (Imaging Associates, Thame, UK). Using a × 20 objective lens, the three microscopic fields with the most intense stromal ACE immunoreativity were selected per section. For each field, the synovial area of interest was delineated interactively, and the area occupied by ACE immunoreactivity was segmented according to grey level. ACE fractional area was defined as the sum of the ACE immunoreactive areas divided by the sum of the synovial areas.
Qualitative assessment of inflammation and quantification of cellularity were determined on haematoxylin and eosin counterstained sections used in saturation studies described above. Using a × 10 objective lens, the three microscopic fields with the most intense cellularity were selected per section. For each field, the synovial area of interest was delineated interactively, and the area occupied by haematoxylin positive nuclei was segmented according to hue. Nuclear fractional area was defined as the sum of the haematoxylin positive areas divided by the sum of the synovial areas.
STATISTICAL ANALYSIS
Descriptive data are expressed as geometric (binding and cellularity data) or arithmetic (ACE fractional area) means (95% confidence intervals). Between group comparisons were made using SPSS for Windows release 6.1 statistical programme (SPSS Inc, Chicago, IL) by Student's t test, or one way analysis of variance with post-hoc comparisons using Duncan's multiple range test and a significance level set at 0.05. Correlations were determined using 
arrow). (D) ACE-LI in the field of a consecutive tissue section that corresponds to the box shown in (C). Intense ACE-LI is localised to stromal cells, particularly those immediately beneath the lining cells and around blood vessels. The small arrow indicates ACE-LI localised to vascular endothelium corresponding to punctate binding in (C). (A) and (C) Reversal prints of film autoradiograms. (B) and (D)
Immunohistochemistry with rabbit polyclonal antihuman ACE, developed with DAB using glucose oxidase/nickel enhancement. Open arrows indicate synovial lining region. Bars = 500 µm. 2, fig 2) . Binding was time dependent, reversible, saturable, and completely inhibited by the non-radiolabelled ACE inhibitors lisinopril and captopril, but not by the neutral endopeptidase inhibitor phosphoramidon (table 1) fig 2) . Binding sites on blood vessels were more dense than on stroma in synovia from patients with osteoarthritis, whereas binding sites on blood vessels had a similar density to those in stroma in rheumatoid arthritis (table 2, fig 1) .
The fraction of synovial section area occupied by ACE immunoreactivity diVered between disease groups (F = 5.736, p = 0.012). ACE fractional area was greater in synovia from patients with rheumatoid arthritis (0.21 (95% CI, 0.14 to 0.28)), than in synovia from patients with osteoarthritis (0.10 (95% CI, 0.03 to 0.18), p < 0.05), and synovia from patients with chondromalacia patellae (0.09 (95% CI, 0.05 to 0.14), p < 0.05). ACE fractional area displayed positive correlation with log 10 stromal [ 
Discussion
Our findings indicate that tissue ACE levels are increased in synovia from patients with rheumatoid arthritis and that this increase is attributable to an increase in the density of ACE bearing stromal cells, rather than to changes in vascular ACE.
The distribution of [ 125 I]351A binding was identical to that of ACE-LI, confirming the localisation of ACE to synovial vascular endothelium, and to fibroblast-like stromal cells, particularly those localised immediately beneath the synovial lining cells. 17 Stromal [ 125 I]351A binding, as defined in this study, included some binding to vascular endothelium, where vessels were small or displayed low density binding that did not allow their discrimination from stroma in the vascular mask. DiVerences in vascular densities between disease groups are unlikely to explain diVerences in stromal [ 125 I]351A binding because two parallel studies using immunoreactivity for CD34 and binding of Ulex europaeus agglutinin-I as endothelial markers did not indicate diVerences in the fraction of synovial section area occupied by endothelium between these disease groups. 27 Furthermore, the endothelial fractional areas (approximately 8%) determined in each of three disease groups in these studies were similar to ACE fractional areas in synovia from patients with chondromalacia patellae or osteoarthritis in this study, and less than half the values for ACE fractional areas in synovia from patients with rheumatoid arthritis. Increased stromal ACE may indicate either an increase density of cells that express ACE, or an increase in ACE expression by stromal cells. Either of these interpretations of our data would be consistent with increased ACE activity in the synovia of patients with rheumatoid arthritis that may contribute to the raised ACE activity observed in synovial fluids from patients with rheumatoid arthritis. 14 15 Cellularity was increased in synovia from patients with rheumatoid arthritis compared with those from patients with osteoarthritis, as indicated by an increased proportion of the section area occupied by haematoxylin positive nuclei. This increase in cellularity was suYcient to explain the increased [ 125 I]351A binding capacity in rheumatoid arthritis, supporting the suggestion that increased stromal ACE reflects an increased number of ACE bearing cells within the synovium. Clarification of whether individual cells express more ACE in synovia from patients with rheumatoid arthritis will require further work on primary cultures of synovial cells.
Increased ACE in tissue stroma has been observed in the heart after myocardial infarction and in hypertension, and in healing skin wounds. 8 9 28 As in synovium, stromal ACE was localised to fibroblast-like cells in these tissues. Cultured fibroblasts and myofibroblasts express ACE mRNA and protein, and display ACE-like enzymatic activity. 5 29 30 ACE expression by fibroblast-like cells is generally lower than by endothelial cells. 31 32 However, fibroblast expression of ACE is subject to upregulation by a variety of factors that are present in inflamed synovium, such as basic fibroblast growth factor. 5 Serum concentrations of angiotensinogen, the precursor of ANG I, are increased, and synovial fluid renin activity is raised in rheumatoid arthritis. 33 34 Increased concentrations both of ANG II precursors and of ACE lead us to suggest that the synovial angiotensin system is activated in rheumatoid arthritis. Furthermore, AT 1 receptor binding and ACE colocalise in human synovium indicating that synovial AT 1 receptors are exposed to locally generated ANG II. 35 ANG II that has been generated by stromal cells may have autocrine eVects on fibroblasts. Synovial inflammation may be regarded as an abnormal repair process in which synovial proliferation leads to joint damage. ANG II, acting through AT 1 receptors, can stimulate fibroblast proliferation and the generation of matrix proteins and growth factors such as transforming growth factor . 4 6 7 ACE is upregulated on cardiac fibroblasts during the tissue repair that follows myocardial infarction. 9 In this model, fibroblast proliferation is inhibited by specific ACE inhibitors and by AT 1 receptor antagonists, consistent with stimulatory roles for endogenous ACE and ANG II. 11 12 Increased stromal ACE may contribute to synovial proliferation and hypertrophy in rheumatoid arthritis by increasing ANG II production within the stromal compartment.
ANG II produced by stromal cells may have paracrine actions on the synovial vasculature, in addition to autocrine eVects on synovial fibroblast-like cells. ANG II is a potent vasoconstrictor, and can stimulate angiogenesis in inflamed tissues. 3 Increased ANG II generation within inflamed synovium therefore may contribute to synovial hypoxia and angiogenesis, each of which has been implicated in the pathogenesis of persistent synovitis. 27 36 In addition to its role in the reninangiotensin system, ACE can inactivate other peptides including bradykinin and substance P. 1 These peptides increase blood flow and plasma extravasation in acute models of inflammation, and may stimulate vascular and connective tissue proliferation in chronic inflammation. [37] [38] [39] Synovial stromal cells and microvascular endothelium bear specific receptors for bradykinin and substance P respectively 40 41 and upregulation of synovial ACE may be important in reducing the pro-inflammatory activities of these peptides.
The ACE inhibitor captopril had eVects that were consistent with a slow acting antirheumatic agent in an open, prospective study of 15 patients with rheumatoid arthritis. 42 ACE inhibition with pentopril, however, was not associated with clinical improvement in rheumatoid arthritis. 43 These equivocal results may reflect the diVerent roles of ACE in multiple regulatory peptide systems. In animal models, eVects of ACE inhibition have sometimes been attributed to potentiation of kinins or substance P, rather than inhibition of ANG II generation. 44 45 Elucidation of the importance of increased synovial ANG II generation in rheumatoid arthritis will require more selective intervention with agents such as the recently developed AT 1 receptor antagonists. 
